BioSpace News Archive

Intercept Pharmaceuticals, Inc. announced new sub-analyses from its Phase 3 POISE trial in primary biliary cholangitis showing the effect of obeticholic acid across a number of key biomarkers of liver health in people living with PBC will be presented at the European Association for the Study of the Liver Congress 2024 being held June 5-8, 2024, in Milan, Italy.

Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that management will participate at several upcoming investor conferences in the United States and Europe during June 2024.

Personalis, Inc. (Nasdaq: PSNL) announced today that data presented at the American Society for Clinical Oncology (ASCO) oral podium talks in Chicago, IL demonstrated that the Personalis NeXT Personal test had exceptional detection rates and performance for early-stage breast cancer and immunotherapy monitoring.

Alimera Sciences, Inc. announced that, pursuant to Nasdaq Listing Rule 5635 and in connection with the appointments of five non-executive employees, the Compensation Committee of the Board of Directors of the Company approved, on May 22, 2024, inducement awards consisting of stock options under the Alimera Sciences, Inc. 2024 Equity Inducement Plan.

Microbot Medical Inc. announced that it has closed its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale of 1,566,669 shares of the Company’s common stock at a purchase price of $1.50 per share of common stock.

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women’s cancers, announced that the Company granted stock options to four new employees to purchase an aggregate of 51,600 shares of the Company’s common stock, effective as of June 3, 2024.

NurExone Biologic Inc.,, a pioneering biopharmaceutical company developing regenerative medicine therapies, is pleased to announce the voting results from its annual general and special meeting of shareholders held on Monday, June 3, 2024 via live webcast.

QUANTRO Therapeutics (QUANTRO), a pioneer in the discovery of first-in-class transcription factor targeting cancer treatments, announced today that the company has reached a key milestone in its joint R&D program with Boehringer Ingelheim.

Lobe Sciences Ltd., a biopharmaceutical company focused on developing transformative medicines to treat diseases with unmet medical needs and rare diseases announced the evaluation of strategic alternatives to improve shareholder value.

Ascentage Pharma announced that it has released updated clinical data of olverembatinib, a third-generation tyrosine kinase inhibitor, in patients with TKI-resistant succinate dehydrogenase -deficient gastrointestinal stromal tumor, in an oral report at the 60th American Society of Clinical Oncology Annual Meeting taking place in Chicago, IL.